Q32 Bio Inc. (QTTB)
(Delayed Data from NSDQ)
$43.68 USD
-1.07 (-2.39%)
Updated Oct 7, 2024 03:59 PM ET
After-Market: $43.46 -0.22 (-0.50%) 4:30 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
QTTB 43.68 -1.07(-2.39%)
Will QTTB be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for QTTB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QTTB
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 91.69%: Read This Before Placing a Bet
QTTB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for QTTB
Q32 Bio Inc. Patent Woes: Navigating the Perilous Waters of Intellectual Property Disputes
Q32 Bio initiated with bullish view at Wells Fargo, here's why
Q32 Bio to Participate in Upcoming September Investor Conferences
Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Immunovant (IMVT) and Q32 Bio (QTTB)